Merck-Moderna mRNA Vaccine Slows Melanoma Return — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna reported in August that adding their mRNA cancer vaccine intismeran autogene to an existing treatment slowed the return and spread of melanoma in a late-stage trial.
- The trial results showed the drug stopped the return of melanoma, the first late-stage validation that mRNA can train the immune system to attack cancer cells.
- Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the field had been waiting "with bated breath" for the intismeran autogene data.
- The Parker Institute for Cancer Immunotherapy, founded by Sean Parker, framed the results as confirming that the decades-old mRNA-immunotherapy concept is ripe for further drug development.
- Researchers are now weighing which additional cancer types to test the approach in and whether mRNA is up to the task beyond melanoma.
- The article frames the moment as a turning point — from proving mRNA cancer vaccines work at all to proving they work at scale across tumor types.
Why it matters: The melanoma data gives Merck and Moderna the first late-stage proof that mRNA cancer vaccines can delay recurrence, shifting the question from "does this work?" to "where else does it work?" That next decision — which tumor types enter the pipeline — determines whether intismeran autogene becomes a one-drug story or a platform that justifies expanded R&D investment across the field.
Ask SkimNews
